HM 101207
Alternative Names: HM-101207Latest Information Update: 30 May 2025
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors; SOS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer